Please login to the form below
RIPK1 inhibitor
This page shows the latest RIPK1 inhibitor news and features for those working in and with pharma, biotech and healthcare.
Sanofi reports positive new data for multiple sclerosis treatment tolebrutinib
Sanofi’s investigational BTK inhibitor, tolebrutinib, has been shown to have a significant effect on the key central nervous system immune mediators that may drive multiple sclerosis (MS) disease progression, according ... phase 2 MS trial design for
Latest news
-
Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors
Rigel already has ongoing pre-clinical activities with its lead CNS penetrant RIPK1 inhibitor candidates. ... The ethos behind RIPK1 inhibitor development is to offer a new kind of approach towards treating a range of autoimmune, inflammatory and
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
